Background: Longitudinal variability in serum IgE levels has not been prospectively studied in people with moderate to severe allergic asthma.

Objective: We investigated change in serum IgE concentrations over 1 year, and its relationship with lung function, asthma control, asthma pharmacotherapy, allergy season, asthma exacerbations, body mass index, and demographic factors.

Methods: Seventeen patients with moderate to severe persistent allergic asthma were followed for 1 year. Variability in serum IgE level was explored using a linear mixed regression model treating a change of 10% or more in IgE concentration and combined change of 10% or more and an absolute change of 50 IU/mL as dichotomous variables.

Results: For consecutive visits every 2 months, the mean percent change in serum IgE level was 23 ± 3 (P < .001). Probability of having a greater than 10% change in serum IgE level in a subsequent visit was 69% (95% CI, 58%-78%; P < .001). Variability in IgE level could have affected clinical decisions for anti-IgE treatment (dosing and/or treatment candidacy) in 7 of 17 patients. There were no statistically significant associations of IgE level variability with demographic characteristics and lung function, exacerbations, allergy season, Asthma Control Test scores, peak flow rates, pharmacotherapy, or body mass index.

Conclusions: Serum IgE concentrations exhibit variability over time among individuals with moderate to severe persistent allergic asthma. The factors that contribute to IgE level variability and the impact of these findings on clinical outcomes deserve further study.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaip.2016.02.007DOI Listing

Publication Analysis

Top Keywords

serum ige
20
moderate severe
12
change serum
12
ige level
12
ige levels
8
patients moderate
8
severe persistent
8
persistent allergic
8
allergic asthma
8
asthma year
8

Similar Publications

Immunoglobulin E, the potential accelerator of comorbid psoriasis and atherosclerosis.

Biomed Pharmacother

January 2025

Laboratory of Medical Mycology & Department of Dermatology, Jining No.1 People's Hospital affiliated to Shandong First Medical University, Jining, Shandong, China. Electronic address:

Immunoglobulin (Ig) E is a key mediator in the induction and maintenance of allergic inflammation, characterized by a Th2-dominated immune response. Recently epidemiological studies have showed that elevated serum total IgE levels or an increased abundance of mast cells (MCs) at the lesion site are observed in psoriatic patients with cardiovascular diseases (CVD), such as atherosclerosis. Although the underlying mechanisms by which IgE synergizing with MCs in promoting these chronic immune-inflammatory diseases remain unclear, the interleukin (IL)-23/IL-17 axis appears to play a crucial role in comorbidity of psoriasis and atherosclerosis.

View Article and Find Full Text PDF

Background/objectives: Upper respiratory tract infections (URTIs) are a significant global health burden, and understanding the immune response is crucial for developing effective diagnostic tools and treatment strategies.

Methods: This study investigated the levels of specific biomarkers in 188 patients with URTIs and their association with demographic factors, comorbidities, and clinical outcomes. Immunoglobulin A (IgA), immunoglobulin E (IgE), neutrophils, serum iron, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were measured.

View Article and Find Full Text PDF

Utility of serum biomarkers in real-world practice for predicting response to omalizumab therapy in patients with chronic spontaneous urticaria.

J Allergy Clin Immunol Glob

February 2025

Department of Internal Medicine, Division of Rheumatology, Allergy and Immunology, Cincinnati, Ohio.

Background: Omalizumab (OMA), a recombinant humanized IgG monoclonal anti-IgE antibody, is approved for treatment for chronic spontaneous urticaria (CSU) refractory to second-generation H-antihistamine (SGAH) therapy. However, currently, there are no validated serum biomarkers to reliably predict response to OMA treatment.

Objective: We explored the real-world clinical utility of using serum biomarkers for predicting response to OMA for CSU patients with disease refractory to high-dose SGAH therapy.

View Article and Find Full Text PDF

The term "asthma-chronic obstructive pulmonary disease (COPD) combined phenotype" describes patients with persistent airflow limitation and features of both asthma and COPD. There is a lack of data on effective treatments for this group, often excluded from asthma or COPD trials. Inhaled corticosteroids (ICS) are standard for asthma, while bronchodilators are key for COPD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!